Ding I, Huang K, Wang X, Greig J R, Miller R W, Okunieff P
Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1002, USA.
Acta Oncol. 1997;36(3):337-40. doi: 10.3109/02841869709001273.
Acidic and basic fibroblast growth factors (FGF(1/2)) myeloprotect mice in single dose total body irradiation (TBI) experiments with a dose modification factor (DMF) of approximately 1.15. CFU-C assay suggests that one of the mechanisms is augmentation of the shoulder of the radiation dose response curve, and thus protection could be greater with fractionation. Four equal fractions of TBI were delivered to C3H/He mice at times 0 h, 8 h, 24 h, and 32 h. FGF(1/2) dose was 3 microg per i.v. injection given 24 and 4 hrs before the first radiation dose. FGF2 treated mice had a significant survival advantage over saline-treated mice with a DMF of 1.22 +/- 0.07 (p < 0.01). Adding a third dose of FGF2, had no additional benefit on LD(50/30) (dose of radiation lethal to 50% of animals measured at day 30) (DMF = 1.23 +/- 0.06, p < 0.01). FGF1 was not as effective with fractionation (DMF = 1.04 +/- 0.03). Increased survival in FGF2 treated mice was due to the a more rapid recovery of bone marrow hematopoietic cells and peripheral WBC, RBC and platelets. FGF2 may prove a useful treatment response modifier in clinical fractionated irradiation.
在单次全身照射（TBI）实验中，酸性和碱性成纤维细胞生长因子（FGF(1/2)）对小鼠具有骨髓保护作用，剂量修正因子（DMF）约为1.15。集落形成单位 - 细胞（CFU - C）测定表明，其中一种机制是增强辐射剂量反应曲线的肩部，因此分次照射时保护作用可能更强。在0小时、8小时、24小时和32小时对C3H/He小鼠进行四次等量的TBI照射。FGF(1/2)剂量为每次静脉注射3微克，在首次辐射剂量前24小时和4小时给药。FGF2处理的小鼠比生理盐水处理的小鼠具有显著的生存优势，DMF为1.22±0.07（p < 0.01）。添加第三剂FGF2对半数致死剂量（LD(50/30)，即第30天测定的使50%动物致死的辐射剂量）没有额外益处（DMF = 1.23±0.06，p < 0.01）。FGF1在分次照射时效果不佳（DMF = 1.04±0.03）。FGF2处理的小鼠生存率提高是由于骨髓造血细胞以及外周白细胞、红细胞和血小板恢复更快。FGF2可能被证明是临床分次照射中一种有用的治疗反应调节剂。
